RecruitingNCT05430971
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Studying Blastic plasmacytoid dendritic cell neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immune Oncology Research Institute
- Principal Investigator
- Astghik Voskanyan, MD, M.DImmune Oncology Research Institute, Yerevan, Armenia
- Enrollment
- 200 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2032
Study locations (20)
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Seattle Children's Cancer and Blood Disorders Center, Seattle, Washington, United States
- Hematology Center named after prof. R. Yeolyan, Yerevan, Armenia
- University of Calgary, Calgary, Alberta, Canada
- Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada
- Cyprus Society of Haematology, Nicosia, Cyprus
- Oncology Center, Mansoura University Faculty of Medicine, Al Mansurah, Egypt
- M. Iashvili Children's Central Hospital, Tbilisi, Georgia
- Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
- Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad, Baghdad, Iraq
- University of Perugia - Azienda Ospedaliera Perugia, Perugia, Italy
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy
- Department of hematology, Kuwait Cancer Control Center, Kuwait City, Kuwait
- Fundeni Clinical Institute, Department of Acute Leukemia, Bucharest, Romania
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05430971 on ClinicalTrials.govOther trials for Blastic plasmacytoid dendritic cell neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523555Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesBeijing Biotech
- RECRUITINGPHASE1, PHASE2NCT06006403Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE2NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03386513Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNAbbVie
- RECRUITINGPHASE1NCT03113643SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer Institute
See all trials for Blastic plasmacytoid dendritic cell neoplasm →